Jiameng Zhang

TL;DR: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS).

TL;DR: To study antibody‐independent contributions of B cells to inflammatory disease activity, and the immune consequences of B‐cell depletion with rituximab, in patients with multiple sclerosis (MS).

TL;DR: A simple sensitivity analysis tool is extended, the index of local sensitivity to nonignorability of the coarsening process in the general coarse-data model is converted into a simple graphical display, and the validity of the method is illustrated.

TL;DR: This paper derives formulas for a range of models and applies the method to evaluate sensitivity to nonignorability in 2 real data examples, one involving missing CD4 counts in an HIV trial and the other involving potentially informatively censored relapse times in a leukemia trial.

TL;DR: A graphical method for analyzing sensitivity of estimates of survival model parameters to small departures from nonignorable censoring is demonstrated and applied to a clinical trial evaluating the survival benefit of a surgically implanted left ventricular assist device in subjects with end-stage heart failure.